WAVE LIFE SCIENCES LTD. Marketable Securities, Unrealized Gain (Loss)
WAVE LIFE SCIENCES LTD. (WVE) reported Marketable Securities, Unrealized Gain (Loss) of -$41.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$41.00K.
- WAVE LIFE SCIENCES LTD. marketable securities, unrealized gain (loss) for the quarter ending 2025-06-30 was $0.00.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month |
|---|---|---|
| 2026-06-30 | -$41.00K 10-Q · filed 2026-07-30 | -$41.00K 10-Q · filed 2026-07-30 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |